文献速递衰弱、肌少症与跌倒老年综合评估

晚期糖基化终产物与代谢组学均独立与衰弱相关:Doetinchem队列纵向研究

Advanced Glycation End-Products and Metabolomics Are Independently Associated With Frailty: The Longitudinal Doetinchem Cohort Study.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2025-01-01

Skin autofluorescence (SAF), reflecting advanced glycation endproducts' accumulation in tissue, has been proposed as a noninvasive aging biomarker. Yet, SAF has not been compared with well-established blood-based aging biomarkers such as MetaboHealth in association with frailty.…

要点

  • SAF与MetaboHealth均独立关联衰弱前期和衰弱,相互调整后关联仍显著。
  • SAF与MetaboHealth联合使用可能增强对年龄相关衰退的评估能力。
  • SAF纵向与衰弱指数变化相关,支持其作为衰老生物标志物的潜力。

核心结论

  • SAF和MetaboHealth均独立与衰弱前期、衰弱及更高衰弱指数评分相关,相互调整后仍保持关联,提示二者捕获衰老过程的不同方面。
  • SAF纵向与衰弱指数变化相关,支持其作为年龄相关衰退生物标志物的临床潜力,与MetaboHealth联合可能进一步增强。

研究设计与样本

  • SAF使用AGE Reader测量,MetaboHealth基于1H-NMR代谢组学计算,采用线性回归和 logistic 回归分析关联,纵向关联通过线性混合模型中的年龄与SAF交互项确定。

主要发现

  • SAF和MetaboHealth每标准差与衰弱前期风险增加相关(SAF OR 1.21 [1.10-1.32],MetaboHealth OR 1.35 [1.24-1.49])。
  • SAF和MetaboHealth每标准差与衰弱风险增加相关(SAF OR 1.70 [1.41-2.06],MetaboHealth OR 1.90 [1.57-2.32])。
  • 相互调整后,SAF和MetaboHealth仍与衰弱前期(SAF OR 1.16 [1.05-1.27],MetaboHealth OR 1.33 [1.21-1.46])和衰弱(SAF OR 1.52 [1.25-1.85],MetaboHealth OR 1.75 [1.43-2.14])相关。
  • SAF和MetaboHealth每标准差与衰弱指数评分升高相关(SAF百分比增加1.35 [1.00-1.70],MetaboHealth 1.87 [1.54-2.20]),相互调整后MetaboHealth仍相关(1.69 [1.35-2.02]),SAF为1.02 [0.68-1.37]。
  • SAF纵向与衰弱指数相关(每单位/年增加百分比0.12 [0.07-0.16])。

临床怎么用

  • SAF可作为无创筛查工具,用于识别衰弱前期和衰弱高风险老年人,辅助老年综合评估。
  • SAF与MetaboHealth联合使用可能提高对年龄相关衰退的评估效能,但需进一步验证。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Skin autofluorescence (SAF), reflecting advanced glycation endproducts' accumulation in tissue, has been proposed as a noninvasive aging biomarker. Yet, SAF has not been compared with well-established blood-based aging biomarkers such as MetaboHealth in association with frailty. Furthermore, no previous study determined the longitudinal association of SAF with frailty. We used 2 382 Doetinchem Cohort Study participants' (aged 46.0-85.4) cross-sectional data, of whom 1 654 had longitudinal SAF measurements. SAF was measured using the AGE Reader. MetaboHealth was calculated on 1H-NMR-metabolomics. Linear regressions were used for the associations of SAF and MetaboHealth on the 36-deficit frailty index and logistic regressions for being pre-frail or frail as determined by the frailty phenotype. Longitudinal associations were determined by an interaction term between age and SAF in a linear mixed model. SAF and MetaboHealth were associated with higher odds of pre-frailty (odd ratios per standard deviation SAF: 1.21 [1.10-1.32], MetaboHealth: 1.35 [1.24-1.49]) and frailty (SAF: 1.70 [1.41-2.06], MetaboHealth: 1.90 [1.57-2.32]). When mutually adjusted, both aging biomarkers remained associated with pre-frailty (SAF: 1.16 [1.05-1.27], MetaboHealth 1.33 [1.21-1.46]) and frailty (SAF: 1.52 [1.25-1.85], MetaboHealth: 1.75 [1.43-2.14]). Additionally, SAF and MetaboHealth were associated with higher frailty index scores (percentage increase per standard deviation SAF: 1.35 [1.00-1.70], MetaboHealth: 1.87 [1.54-2.20]), also after mutual adjustment (SAF: 1.02 [0.68-1.37], MetaboHealth: 1.69 [1.35-2.02]). SAF was also longitudinally associated with the frailty index (percentage per unit/year increase: 0.12 [0.07-0.16]). The mutual independence of SAF and MetaboHealth implies they capture distinct aspects of the aging process. Altogether, these findings emphasize SAF's clinical potential as an age-related decline biomarker, which could be further enhanced when combined with MetaboHealth.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Kuiper LM, Picavet HSJ, Rietman ML, et al. Advanced Glycation End-Products and Metabolomics Are Independently Associated With Frailty: The Longitudinal Doetinchem Cohort Study. J Gerontol A Biol Sci Med Sci. 2025. PMID: 39607723. doi:10.1093/gerona/glae272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。